Figure 3
![Figure 3. OS estimates according to randomization and European Leukemia Net genetic group. (A) Favorable and intermediate I/II groups. Median OS times for patients who received LDC (n = 28) and LDC + volasertib (n = 22) were 7.8 and 9.8 months, respectively (HR, 0.54; 95% confidence interval [CI], 0.29-1.02). (B) Adverse group. Median OS times for patients who received LDC (n = 14) and LDC + volasertib (n = 14) were 3.3 and 5.9 months, respectively (HR, 0.63; 95% CI, 0.29-1.40). Database snapshot November 7, 2013.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/127/1/10.1182_blood-2015-07-604538/5/71f3.jpeg?Expires=1724198452&Signature=jcOQhdWefpIEfhlBlL33i2bRQfbef~BdUHaLfo6M2RW27-Y1rU6EvMSezHh~eED2N1NBWvZFwgGbtGo5FRikiy7rZZtcxyObKVziKQsVAQJhif24WsRcop0~ogmvCjBwo4JK8yPN9DDPiGD9pjqPvN5KV8QxqBp8eKb~Qla~5LnMcvyi4zx62LNHJVlOqhTlbDl4y4uoleMJ1oE4~bco0ASpfaNWsst7mpEWj6REN2-yVCrFFG2d7O9Of2zuVejAvlMbCvb67WntvV0~xBmTo3XIYDz~cCaaIKq0j2-xGOu5WNHvcR~CnKA~llyrSbva2t8VV4Acz39OclQfVC3aRQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
OS estimates according to randomization and European Leukemia Net genetic group. (A) Favorable and intermediate I/II groups. Median OS times for patients who received LDC (n = 28) and LDC + volasertib (n = 22) were 7.8 and 9.8 months, respectively (HR, 0.54; 95% confidence interval [CI], 0.29-1.02). (B) Adverse group. Median OS times for patients who received LDC (n = 14) and LDC + volasertib (n = 14) were 3.3 and 5.9 months, respectively (HR, 0.63; 95% CI, 0.29-1.40). Database snapshot November 7, 2013.
